The 2022 revision of EU GMP Annex 1 changed how sterile manufacturers approach contamination risk. For the first time, a documented, facility-wide contamination control strategy (CCS) became a formal expectation rather than a collection of individual procedures. Achieving Annex 1 compliance now depends on an organization’s ability to connect its controls, justify them through scientific risk assessment, and demonstrate that they remain effective.
This article explains how manufacturers can develop a robust contamination control strategy that supports regulatory expectations and protects patients throughout every stage of aseptic processing.
Why a Contamination Control Strategy Sits at the Center of Annex 1 Compliance
Annex 1 states that a contamination control strategy should be implemented across the facility to define critical control points and evaluate the effectiveness of the design, procedural, technical, and organizational controls used to manage contamination risks.
In practice, the CCS is not simply a document maintained for inspection purposes. It is a comprehensive framework that connects potential sources of contamination, including microbial, particulate, and chemical risks, with the controls established to prevent or reduce those risks.
The revised Annex 1 expects manufacturers to address a wide range of elements within the CCS, including facility and process design, premises and equipment, utilities, personnel, raw materials, sterilization processes, cleaning and disinfection, environmental monitoring, and ongoing trending and investigation. The FDA’s guidance on aseptic processing follows a similar approach, emphasizing that sterility assurance depends on a coordinated system of controls rather than any single safeguard.
Managing Risk as the Foundation
A contamination control strategy is only effective when it is supported by a strong risk management approach. Annex 1 is built around Quality Risk Management principles, requiring manufacturers to identify contamination hazards, evaluate their potential impact, and implement controls that are appropriate for the level of risk.
Building the Risk Assessment
Effective CCS development begins with a structured assessment that identifies contamination pathways throughout the manufacturing process, from facility entry through final filling. Each identified risk should be connected to a specific control strategy and a method for verifying that the control remains effective.
This level of traceability allows manufacturers to demonstrate that contamination risks have been considered, addressed, and continuously monitored. It also provides regulators with clear evidence that controls are based on scientific understanding rather than historical practice alone.
Reducing Human Intervention
Both Annex 1 and FDA guidance identify personnel as one of the greatest potential sources of contamination during aseptic processing. Because of this, manufacturers are encouraged to reduce direct human interaction with critical processing areas through the use of barrier technologies, restricted access barrier systems (RABS), isolators, and automation.
When interventions cannot be eliminated, they must be carefully evaluated, minimized, and incorporated into aseptic process simulations to demonstrate that they do not compromise sterility assurance.
PUPSIT and Sterilizing Filtration
Pre-use post-sterilization integrity testing (PUPSIT) remains one of the most discussed requirements introduced in Annex 1. Paragraph 8.87 states that the integrity of a sterilized filter assembly should be verified before use to confirm that the filter has not been damaged during preparation, sterilization, or installation. A sterilizing-grade filter used for fluid sterilization should also undergo a non-destructive integrity test after use.
The rationale behind PUPSIT is straightforward. A filter damaged during handling or sterilization could allow contaminants to pass through, and relying only on post-use testing may not identify the issue until after product quality has already been impacted.
Annex 1 establishes PUPSIT as the expected approach while allowing alternative strategies when a comprehensive, documented risk assessment demonstrates that another method provides equivalent protection with appropriate controls.
Environmental Monitoring and Aseptic Processing Controls
Environmental monitoring provides the data needed to demonstrate that contamination controls remain effective. Annex 1 increased expectations surrounding cleanroom monitoring, particularly within Grade A and Grade B environments where continuous monitoring and real-time particle data are becoming increasingly important.
A comprehensive CCS should define monitoring strategies, establish alert and action levels, address routine viable and non-viable monitoring of air, surfaces, and personnel, and establish processes for investigating excursions.
Trending and Investigation
Environmental monitoring data provides the greatest value when analyzed over time. Annex 1 and FDA guidance emphasize the importance of trending data to identify potential shifts before they develop into significant contamination events.
Effective investigations should focus on identifying root causes rather than addressing only immediate symptoms. Findings should then be incorporated back into the CCS through corrective and preventive actions, ensuring the strategy evolves as processes, equipment, and facility conditions change.
Validating the Process
Aseptic process simulations, commonly known as media fills, remain a critical component of aseptic process validation. FDA guidance recommends simulating worst-case manufacturing conditions using sterile nutrient media, incubating filled units, and investigating any contaminated results.
These simulations provide evidence that the combined controls outlined in the CCS can consistently maintain sterility under realistic operating conditions.
Inspection Readiness
Regulators increasingly view the CCS as a central component of inspection readiness. A well-developed strategy allows manufacturers to demonstrate how contamination risks are identified, controlled, monitored, and improved through an integrated system.
When deficiencies are identified, responses should address underlying system weaknesses rather than isolated events. This approach reflects the intent of Annex 1, which emphasizes proactive contamination control and continuous improvement.
Maintaining a current, cross-referenced CCS supported by data trending and documented improvements is one of the most effective ways to remain prepared for inspections throughout the product lifecycle.
Conclusion
Annex 1 compliance is no longer focused on meeting individual requirements in isolation. Success depends on developing a contamination control strategy that connects facility design, risk management, PUPSIT, environmental monitoring, and validation into one coordinated approach to aseptic processing.
Manufacturers that treat the CCS as a dynamic, data-driven program rather than a static document will be better positioned to maintain product quality, meet regulatory expectations, and protect patients.
About PSC Biotech®
Founded in 1996, PSC Biotech® has spent three decades helping life sciences organizations ensure their products are developed, manufactured, and distributed in compliance with applicable regulatory requirements.
As AI-enabled tools become increasingly integrated into GxP manufacturing, quality systems, and regulatory operations, PSC Biotech helps clients implement governance and validation approaches that support compliant innovation.
Operating in 52 countries with teams across North America, Europe, Asia, the Middle East, and Australia, PSC Biotech partners with clients to bring life-saving products to market.
Explore PSC Biotech services at biotech.com and follow us on LinkedIn to stay up to date.
References
European Commission. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1: Manufacture of Sterile Medicinal Products (2022).
European Commission / ECA reference to Annex 1 Paragraph 8.87 on PUPSIT.
U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing, Current Good Manufacturing Practice (2004).